Sebastian Gensior

Strategy was once a noun. Then someone turned it into a 2x2 matrix and started charging €400/hour for it. In the beginning was the memo. Then came the workshop. And lo, the workshop begat the brainstorm, and the brainstorm begat The Framework™. And thus the modern consultant emerged, blinking

Foundations of a Gene Therapy Pioneer (1992–2010) bluebird bio began not as the vibrant name suggests, but as a modest startup called Genetix Pharmaceuticals in April 1992. Founded by two MIT researchers, Philippe Leboulch and Irving London, the company was grounded in a radical idea for its time: using

In the spirit of Thatcher—and with apologies to everyone who just spat out their ethically sourced oat milk—here’s a gentle reminder for anyone who’s ever outsourced conviction to a consultant: If you’re a founder relying on beautifully formatted advice to hide your own indecision, Thatcher

The biotechnology sector continuously faces significant funding challenges, balancing the enormous costs of clinical development with the necessity of minimizing dilution for early investors and founders. Recently, royalty financing has emerged as a strategic and expanding source of non-dilutive capital. It provides capital in exchange for future product revenues, creating

If there’s one thing that consistently frustrates me, it’s how pseudoscientific claims are dressed up as life-saving innovations. These misleading tactics often prey on our fears and uncertainties, particularly when we’re facing something as terrifying as cancer. Labels like “clinically proven,” “FDA registered,” or “vital essence” are

Conflicting Narratives in a Growing Sector China’s early-stage biotech and drug development startups have been riding a seesaw of soaring optimism and sobering reality. On one side are upbeat proclamations of a biotech boom – thousands of new firms, gleaming research parks, and bold plans to rival Western pharma giants.

Biotech IPOs: A Tale of Two Continents Not long ago, biotech firms queued eagerly for public markets, buoyed by cheap money and boundless optimism. The IPO window, however, slammed shut in 2022 under pressure from rising interest rates, stubborn inflation, and skeptical investors. Since then, biotech companies on both sides

You’re sitting across from a General Partner (GP) at a biotech-focused venture capital (VC) fund. They’re presenting their latest performance report, brimming with confidence. “We’ve achieved a PME ratio of 1.4,” the GP declares, leaning back with a satisfied smile. “This proves we’re outperforming public

The global biotech venture capital boom of the late 2010s has decisively given way to a sobering downturn. After a decade of exuberance, investment levels in mid-2025 have retreated to where they stood in the early 2010s (biospace.com). The industry is emerging from a classic cycle of boom and

Real-World Evidence (RWE) has become one of the most discussed innovations in healthcare decision-making, promising to bridge the gap between the highly controlled world of clinical trials and the unpredictable realities of everyday medical practice. By leveraging data from routine clinical care, patient registries, claims databases, and even wearable technology,